Table 2. Correlations between pathologic subtypes and EGFR, KRAS mutations.
| Pathologic types | EGFR Mu | EGFR WT | KRAS Mu | KRAS WT |
|---|---|---|---|---|
| Adenocarcinoma | 111 | 170 | 23 | 189 |
| SqCC | 5 | 64 | 3 | 61 |
| Large cell carcinoma | 15 | 13 | ||
| NSCLC | 1 | 6 | 1 | 11 |
| SCLC | 12 | 1 | 11 | |
| Double primary(adeno + SqCC) | 2 | 1 | 7 | |
| Pleomorphic carcinoma | 2 | 1 | ||
| Metastatic carcinoma | 6 | |||
| Clear cell carcinoma | 1 | |||
| Malignant melanoma | 1 | |||
| Mucoepidermoid carcinoma | 2 | 2 | ||
| Adenoca. | 113 (39.78) | 171 (60.22) | 23(10.50) | 196 (89.50) |
| Non-adenoca. | 6 (6.96) | 107 (93.04) | 5 (4.80) | 99 (95.20) |
| P < 0.001 | P < 0.001 |